DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mesna (Mesna) - Candida Test Positive - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Candida Test Positive (18)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mesna where reactions include candida test positive. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-18

Patient: female, weighing 13.1 kg (28.8 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
    Indication: Sarcoma Metastatic

Vinorelbine Tartrate
    Dosage: last dose prior to sae:20/jun/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Doxorubicin Hydrochloride
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Cyclophosphamide
    Dosage: last dose prior to sae 23/jun/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Fluconazole; Levomepromazine; Cotrim; Docusate; Ondansetron; Gentamicin; Morphine; Moviprep; Neupogen; Neupogen; Dihydrocodeine Bitartrate INJ; Acetaminophen; Ondansetron; Docusate; Docusate; Piperacillin and Tazobactam; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-13

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine and Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Vinorelbine Tartrate
    Dosage: last dose prior to sae:20/jun/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Cyclophosphamide
    Dosage: last dose prior to sae 23/jun/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Ondansetron; Ondansetron; Gentamicin; Moviprep; Moviprep; Levomepromazine; Moviprep; Docusate; Cotrim; Docusate; Neupogen; Acetaminophen; Levomepromazine; Neupogen; Ondansetron; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Docusate; Morphine; Emollient Cream (Unk Ingredients)



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-06

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Cyclophosphamide
    Dosage: last dose prior to sae 23/jun/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vinorelbine Tartrate
    Dosage: last dose prior to sae:20/jun/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Levomepromazine; Docusate; Piperacillin and Tazobactam; Cotrim; Gentamicin; Ondansetron; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron; Docusate; Moviprep; Neupogen; Acetaminophen; Levomepromazine; Moviprep; Docusate



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-02

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Vinorelbine Tartrate
    Dosage: last dose prior to sae 08/may/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Cyclophosphamide
    Dosage: last dose prior to sae 06/06/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 21/05/2012
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Moviprep; Cotrim; Morphine; Docusate; Docusate; Gentamicin; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Piperacillin and Tazobactam; Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Docusate; Neupogen



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2012-05-29

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Vinorelbine Tartrate
    Dosage: last dose prior to sae 08/may/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 08/jul/2012
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Cyclophosphamide
    Dosage: last dose prior to sae 11/may/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Other drugs received by patient: Fluconazole; Acetaminophen; Docusate; Emollient Cream (Unk Ingredients); Ondansetron; Ondansetron; Docusate; Morphine; Moviprep; Moviprep; Neupogen; Gentamicin; Moviprep; Ondansetron; Levomepromazine; Cotrim; Neupogen; Ondansetron; Levomepromazine; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Docusate



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-02-14

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Other drugs received by patient: Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Docusate; Docusate; Morphine; Neupogen; Emollient Cream (Unk Ingredients); Levomepromazine; Docusate; Neupogen; Ondansetron; Moviprep; Moviprep; Piperacillin and Tazobactam; Ondansetron; Paracetamol; Cotrim; Gentamicin; Dihydrocodeine Bitartrate INJ



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-01-18

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Other drugs received by patient: Acetaminophen; Ondansetron; Moviprep; Neupogen; Levomepromazine; Levomepromazine; Gentamicin; Emollient Cream (Unk Ingredients); Docusate; Piperacillin and Tazobactam; Morphine; Ondansetron; Neupogen; Ondansetron; Docusate; Moviprep; Ondansetron; Fluconazole; Docusate; Cotrim; Dihydrocodeine Bitartrate INJ



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2012-01-12

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, RED Blood Cell Count Decreased, Febrile Neutropenia, Platelet Count Decreased, Blood Sodium Decreased, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin Hydrochloride
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Levomepromazine; Levomepromazine; Docusate; Piperacillin and Tazobactam; Moviprep; Ondansetron; Neupogen; Neupogen; Cotrim; Ondansetron; Docusate; Docusate; Gentamicin; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Morphine; Acetaminophen; Ondansetron; Moviprep; Emollient Cream (Unk Ingredients)



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2012-01-10

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Haemoglobin Decreased, Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Blood Creatinine Increased, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Morphine; Moviprep; Ondansetron; Cotrim; Moviprep; Emollient Cream (Unk Ingredients); Dihydrocodeine Bitartrate INJ; Acetaminophen; Piperacillin and Tazobactam; Ondansetron; Fluconazole; Neupogen; Ondansetron; Docusate; Docusate; Neupogen; Ondansetron; Levomepromazine; Levomepromazine; Docusate; Gentamicin



Possible Mesna side effects in male

Reported by a physician from United States on 2011-12-23

Patient: male

Reactions: Vomiting, Pain, Tachycardia, Rhinorrhoea, Pyrexia, Irritability, Candida Test Positive, Neutropenic Infection, Escherichia Test Positive, Diarrhoea, Feeling Hot, Tachypnoea, Septic Shock, Cough, Infection

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Indication: Sarcoma
    Start date: 2001-10-02

Cisplatin
    Indication: Sarcoma
    Start date: 2001-10-02

Methotrexate
    Indication: Sarcoma
    Start date: 2001-10-02

Doxorubicin HCL
    Indication: Sarcoma
    Start date: 2001-10-02

Trastuzumab
    Dosage: over 90 minutes on day 1, every week for 37 weeks
    Indication: Sarcoma
    Start date: 2001-10-02

Mesna

Filgrastim
    Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
    Indication: Sarcoma
    Start date: 2001-10-02

Leucovorin Calcium
    Administration route: Oral
    Indication: Sarcoma
    Start date: 2001-10-02

Etoposide
    Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
    Indication: Sarcoma
    Start date: 2001-10-02

Trastuzumab
    Dosage: on day 1(loading dose)
    Start date: 2001-10-02

Dexrazoxane Hydrochloride
    Indication: Sarcoma
    Start date: 2001-10-02

Mesna
    Dosage: then over 15 minutes at hours 8,11,14 post infosamide at 1.8 g/m2 over 4 hours daily for 5 days
    Indication: Sarcoma
    Start date: 2001-10-02



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2011-12-08

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Other drugs received by patient: Acetaminophen; Cotrim; Moviprep; Docusate; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Morphine; Gentamicin; Neupogen; Emollient Cream (Unk Ingredients); Docusate; Neupogen; Ondansetron; Fluconazole; Levomepromazine; Levomepromazine; Ondansetron; Ondansetron; Ondansetron; Moviprep



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2011-12-07

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Fluconazole; Piperacillin and Tazobactam; Ondansetron HCL; Ondansetron HCL; Moviprep; Ondansetron HCL; Docusate; Neupogen; Emollient Cream (Unk Ingredients); Acetaminophen; Levomepromazine; Levomepromazine; Cotrim; Ondansetron HCL; Docusate; Moviprep; Dihydrocodeine Bitartrate INJ; Gentamicin; Morphine; Neupogen



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-12-05

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Acetaminophen; Emollient Cream (Unk Ingredients); Cotrim; Piperacillin and Tazobactam; Moviprep; Levomepromazine; Docusate; Gentamicin; Neupogen; Fluconazole; Ondansetron; Morphine; Ondansetron; Moviprep



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-11-29

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Neupogen; Ondansetron; Fluconazole; Piperacillin and Tazobactam; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Paracetamol; Cotrim; Gentamicin; Moviprep; Docusate; Levomepromazine



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-11-14

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Docusate; Moviprep; Acetaminophen; Cotrim; Morphine; Emollient Cream (Unk Ingredients); Levomepromazine; Piperacillin and Tazobactam; Fluconazole; Gentamicin; Ondansetron; Moviprep; Neupogen



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-11-11

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Gentamicin; Levomepromazine; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Moviprep; Fluconazole; Cotrim; Ondansetron; Docusate; Morphine; Neupogen; Piperacillin and Tazobactam



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-10-18

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cycle last doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Acetaminophen; Cotrim; Neupogen; Levomepromazine; Ondansetron; Piperacillin and Tazobactam; Fluconazole; Gentamycin Sulfate; Ondansetron; Docusate; Morphine; Moviprep; Moviprep



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2011-10-05

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 09 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cycle last doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin Hydrochloride
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Gentamycin Sulfate; Piperacillin and Tazobactam; Ondansetron; Ondansetron; Morphine; Acetaminophen; Fluconazole; Levomepromazine; Cotrim; Moviprep; Docusate; Moviprep; Neupogen

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017